| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina and 2 Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Requests for reprints: Andrew S. Kraft, Director Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425. E-mail: kraft{at}musc.edu
Previously, we showed that the proteasome inhibitor bortezomib/Velcade (formerly PS-341) synergizes with the protein tumor necrosis factor 
–related apoptosis-inducing ligand (TRAIL), a ligand for certain death receptors, to induce apoptosis in cell lines derived from prostate and colon cancers. Because apoptosis is often triggered by BH3-only proteins of the Bcl-2 family, we have explored the hypothesis that bortezomib contributes to the apoptosis by up-regulating their levels. Indeed, bortezomib induced increases of Bik and/or Bim in multiple cell lines but not notably of two other BH3-only proteins (Puma and Bid) nor other family members (Bax, Bak, Bcl-2, and Bcl-xL). The increase in Bik levels seems to reflect inhibition by bortezomib of its proteasome-mediated degradation. Importantly, both Bik and Bim seem central to the proapoptotic function of bortezomib, because mouse embryo fibroblasts in which the genes for both Bik and Bim had been disrupted were refractory to its cytotoxic action. Similarly, the synergy between bortezomib and TRAIL in killing human prostate cancer cells was impaired in cells in which both Bik and Bim were down-regulated by RNA interference. Further evidence that bortezomib acts through the mitochondrial pathway regulated by the Bcl-2 family is that deficiency for APAF-1, which acts downstream of Bcl-2, also blocked its apoptotic effect. These results implicate BH3-only proteins, in particular both Bik and Bim, as important mediators of the antitumor action of bortezomib and establish their role in its enhancement of TRAIL-induced apoptosis.
Key Words: Bortezomib • Bim • Bik • TRAIL • RNAi
Grant support: Department of Defense grant DAMD 17-01-0045 (A.S. Kraft), NIH grant CA10471 (A.S. Kraft), Leukemia and Lymphoma Society Specialized Center of Research grant (J.M. Adams), and National Health and Medical Research Council program grant (J.M. Adams).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: M. Nikrad, T. Johnson, and A.S. Kraft contributed equally to this work. M. Nikrad is currently at the Department of Molecular and Cellular Development, University of Colorado, Campus Box 347, Boulder, CO, 80309-0347. T. Johnson is currently at the Department of Surgery, University of Colorado Health Sciences Center, Denver, CO 80262.
3 P. Bouillet et al., unpublished results.
4 L. Coultas et al., unpublished results.
Received 9/24/04; revised 11/30/04; accepted 1/ 5/05.
This article has been cited by other articles:
|
|
 |
|
  C. Li, R. Li, J. R. Grandis, and D. E. Johnson Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells Mol. Cancer Ther., June 1, 2008; 7(6): 1647 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Shanker, A. D. Brooks, C. A. Tristan, J. W. Wine, P. J. Elliott, H. Yagita, K. Takeda, M. J. Smyth, W. J. Murphy, and T. J. Sayers Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody J Natl Cancer Inst, May 7, 2008; 100(9): 649 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kandasamy and A. S. Kraft Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region Mol. Cancer Ther., May 1, 2008; 7(5): 1091 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-T. Liu, S. G. Agrawal, J. G. Gribben, H. Ye, M.-Q. Du, A. C. Newland, and L. Jia Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL Blood, March 1, 2008; 111(5): 2797 - 2805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Koschny, J. Sykora, H. Walczak, T. M. Ganten, T. L. Haas, M. R. Sprick, H. Holland, P. Ahnert, W. Krupp, J. Meixensberger, et al. Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL Clin. Cancer Res., November 1, 2007; 13(21): 6541 - 6542. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Subramanian, S. Vijayalingam, E. Lomonosova, L.-j. Zhao, and G. Chinnadurai Evidence for Involvement of BH3-Only Proapoptotic Members in Adenovirus-Induced Apoptosis J. Virol., October 1, 2007; 81(19): 10486 - 10495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Voortman, T. P. Resende, M. A.I. Abou El Hassan, G. Giaccone, and F. A.E. Kruyt TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib Mol. Cancer Ther., July 1, 2007; 6(7): 2103 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Y. Fu, S. K. Sukumaran, and V. C. Yu Inhibition of ubiquitin-mediated degradation of MOAP-1 by apoptotic stimuli promotes Bax function in mitochondria PNAS, June 12, 2007; 104(24): 10051 - 10056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, P. Yue, S. Chen, L. Hu, S. Lonial, F. R. Khuri, and S.-Y. Sun The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells Cancer Res., May 15, 2007; 67(10): 4981 - 4988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-X. Ding, H.-M. Ni, X. Chen, J. Yu, L. Zhang, and X.-M. Yin A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells Mol. Cancer Ther., March 1, 2007; 6(3): 1062 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-Z. Ying, H.-G. Zhang, and P. W. Sanders EGF Receptor Activity Modulates Apoptosis Induced by Inhibition of the Proteasome of Vascular Smooth Muscle Cells J. Am. Soc. Nephrol., January 1, 2007; 18(1): 131 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Fribley, B. Evenchik, Q. Zeng, B. K. Park, J. Y. Guan, H. Zhang, T. J. Hale, M. S. Soengas, R. J. Kaufman, and C.-Y. Wang Proteasome Inhibitor PS-341 Induces Apoptosis in Cisplatin-resistant Squamous Cell Carcinoma Cells by Induction of Noxa J. Biol. Chem., October 20, 2006; 281(42): 31440 - 31447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hur, D. W. Bell, K. L. Dean, K. R. Coser, P. C. Hilario, R. A. Okimoto, E. M. Tobey, S. L. Smith, K. J. Isselbacher, and T. Shioda Regulation of Expression of BIK Proapoptotic Protein in Human Breast Cancer Cells: p53-Dependent Induction of BIK mRNA by Fulvestrant and Proteasomal Degradation of BIK Protein. Cancer Res., October 15, 2006; 66(20): 10153 - 10161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Aleo, C. J. Henderson, A. Fontanini, B. Solazzo, and C. Brancolini Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis. Cancer Res., September 15, 2006; 66(18): 9235 - 9244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Khanbolooki, S. T. Nawrocki, T. Arumugam, R. Andtbacka, M. S. Pino, R. Kurzrock, C. D. Logsdon, J. L. Abbruzzese, and D. J. McConkey Nuclear factor-{kappa}B maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2251 - 2260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Y. Yeung, D.-C. Huang, and F. A. Sinicrope PS-341 (Bortezomib) Induces Lysosomal Cathepsin B Release and a Caspase-2-dependent Mitochondrial Permeabilization and Apoptosis in Human Pancreatic Cancer Cells J. Biol. Chem., April 28, 2006; 281(17): 11923 - 11932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sohn, G. Totzke, F. Essmann, K. Schulze-Osthoff, B. Levkau, and R. U. Janicke The proteasome is required for rapid initiation of death receptor-induced apoptosis. Mol. Cell. Biol., March 1, 2006; 26(5): 1967 - 1978. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
